Drug Profile
Research programme: overactive bladder therapies - Scion
Alternative Names: Overactive bladder therapies research programme - ScionLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Scion Pharmaceuticals
- Class Small molecules
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Overactive bladder in USA
- 22 Jun 2005 Preclinical trials in Overactive bladder in USA (unspecified route)